Vida Ventures overview
Stories about Vida Ventures
Vida Ventures targets $750m for latest fund
The Boston-based fund manager launches its latest venture capital and growth equity vehicle.
Vida Ventures targets $750m for third fund
Vida Ventures is seeking to raise $750 million for its third fund, according to an SEC filing.
Vida Ventures hires CFO/COO
Vida Ventures has named Jean-Philippe Kouakou-Zebouah as chief financial and chief operating officer. Previously, he worked at Versant Ventures where he was senior vice president of finance.
Vida Ventures raised $537 mln toward a second fund
Vida Ventures, a Boston, Massachusetts-based life sciences-focused venture firm raised $537 million towards its second fund, according to a regulatory document https://www.sec.gov/Archives/edgar/data/1776851/000177685119000001/xslFormDX01/primary_doc.xml
Allogene Therapeutics grabs funding from Vida Ventures
South San Francisco-based Allogene Therapeutics, a biotech company focused on cancer treatment, has secured an undisclosed amount of funding. The investor was Vida Ventures.
Vida Ventures raises $254.8 mln venture capital fund
Vida Ventures has raised a $254.8 million venture capital fund, according to a filing with the SEC.
Vida Ventures contact information
Offices
10100 Santa Monica Blvd, Floor 15, Los Angeles, 90067, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Ms. Kate Bechtold | Job titleSenior Director of Investor Relations and Communications | LocationLos Angeles, United States | Email  ---------- |
| Key ContactMr. Arie Belldegrun | Job titleFounder and Senior Managing Director | LocationBoston, United States | Email ------- |
| Mr. Jean Philippe Kouakou-Zebouah | Job titleChief Financial Officer and Chief Operating Officer | LocationLos Angeles, United States | Email ----------- |
| Mr. Fred Cohen | Job titleCo-Founder and Senior Managing Director | LocationLos Angeles, United States | Email --------- |
Vida Ventures funds managed
Funds in market: 1
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size ------- | Open dateSep 2026 | Strategy --------- | |
Closed funds: 4
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ----- | Close dateJun 2021 | Strategy ------ | |
Fund size ---------- | Close dateJul 2019 | Strategy --------- | |
Fund size ------- | Close dateApr 2019 | Strategy ----- | |
Stories that mention Vida Ventures
Boston Therapeutics rakes in $150m Series C
Frazier Life Sciences and Lightspeed Venture Partners led the round.
Side Letter: Leonard Green's mega-GP-led; another OMERS PE departure
Leonard Green & Partners has closed one of the largest GP-led deals ever. Plus: Highlights from yesterday's AVCA conference and another departure from OMERS PE. Here's today's brief, for our valued subscribers only.
Texas County confirms $75m commitment
The US public pension fund has backed Vida Venture's third vehicle, which is targeted at $750m.
TCDRS confirms $75m commitment
The US public pension fund has backed Vida Venture's third biotech and life-science vehicle.
Centessa Pharmaceuticals reels in $250m Series A
Centessa Pharmaceuticals, a drug developer, has raised $250 million in Series A financing.
Scorpion Therapeutics picks up $162m Series B
Scorpion Therapeutics, Inc., a next-generation precision oncology company, has raised $162 million in Series B financing.
IconOVir Bio snags $77m Series A
IconOVir Bio Inc., a preclinical-stage biotechnology company, has raised $77 million in Series A financing.
Locanabio pulls in $100m Series B
Locanabio Inc, an RNA-targeting gene therapy company, has raised $100 million in Series B financing.